Display options
Cite
Fasching PA, Häberle L, Rack B, et al. Clinical validation of genetic variants associated with . Oncotarget. 2017;8(44):78133-78143doi: 10.18632/oncotarget.17726.
Fasching, P. A., Häberle, L., Rack, B., Li, L., Hein, A., Ekici, A. B., Reis, A., Lux, M. P., Cunningham, J. M., Ruebner, M., Jenkins, G., Fridley, B., Schneeweiss, A., Tesch, H., Lichtenegger, W., Fehm, T., Heinrich, G., Rezai, M., Beckmann, M. W., Janni, W., Weinshilboum, R. M., & Wang, L. (2017). Clinical validation of genetic variants associated with . Oncotarget, 8(44), 78133-78143. https://doi.org/10.18632/oncotarget.17726
Fasching, Peter A, et al. "Clinical validation of genetic variants associated with ." Oncotarget vol. 8,44 (2017): 78133-78143. doi: https://doi.org/10.18632/oncotarget.17726
Fasching PA, Häberle L, Rack B, Li L, Hein A, Ekici AB, Reis A, Lux MP, Cunningham JM, Ruebner M, Jenkins G, Fridley B, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L. Clinical validation of genetic variants associated with . Oncotarget. 2017 May 09;8(44):78133-78143. doi: 10.18632/oncotarget.17726. eCollection 2017 Sep 29. PMID: 29100455; PMCID: PMC5652844.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 May 09;8(44):78133-78143. doi: 10.18632/oncotarget.17726. eCollection 2017 Sep 29.

Clinical validation of genetic variants associated with .

Oncotarget

Peter A Fasching, Lothar Häberle, Brigitte Rack, Liang Li, Alexander Hein, Arif B Ekici, Andre Reis, Michael P Lux, Julie M Cunningham, Matthias Ruebner, Gergory Jenkins, Brooke Fridley, Andreas Schneeweiss, Hans Tesch, Werner Lichtenegger, Tanja Fehm, Georg Heinrich, Mahdi Rezai, Matthias W Beckmann, Wolfgang Janni, Richard M Weinshilboum, Liewei Wang

Affiliations

  1. Department of Gynecology and Obstetrics, Erlangen University Hospital, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  2. Department of Medicine, Division of Hematology/Oncology, University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA.
  3. Department of Gynecology and Obstetrics, Biostatistics Unit, Erlangen University Hospital, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
  4. Department of Gynecology and Obstetrics, Ludwig-Maximilians-University Munich, Munich, Germany.
  5. Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Mayo Medical School-Mayo Foundation, Rochester, MN, USA.
  6. Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  7. Institute of Human Genetics, Erlangen University Hospital, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
  8. Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, MN, USA.
  9. Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
  10. Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA.
  11. Division of Gynecologic Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
  12. Department of Oncology, Onkologie Bethanien, Frankfurt, Germany.
  13. Department of Gynecology and Obstetrics, Charité University Hospital, Campus Virchow, Berlin, Germany.
  14. Department of Gynecology and Obstetrics, Düsseldorf University Hospital, Heinrich Heine University, Düsseldorf, Germany.
  15. Department of Gynecologic Oncology, Schwerpunktpraxis für Gynäkologische Onkologie, Fürstenwalde, Germany.
  16. Department of Breast Diseases, Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany.
  17. Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.

PMID: 29100455 PMCID: PMC5652844 DOI: 10.18632/oncotarget.17726

Abstract

Hematotoxicity is one of the major side effects of chemotherapy. The aim of this study was to examine the association between single nucleotide polymorphisms (SNPs) and hematotoxicity in breast cancer patients in a subset of patients of the SUCCESS prospective phase III chemotherapy study. All patients (n = 1678) received three cycles of 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) followed by three cycles of docetaxel or docetaxel/gemcitabine, depending on randomization. Germline DNA was genotyped for 246 SNPs selected from a previous genome-wide association study (GWAS) in a panel of lymphoblastoid cell lines, with gemcitabine toxicity as the phenotype. All SNPs were tested for their value in predicting grade 3 or 4 neutropenic or leukopenic events (NLEs). Their prognostic value in relation to overall survival and disease-free survival was also tested. None of the SNPs was found to be predictive for NLEs during treatment with docetaxel/gemcitabine. Two SNPs in and close to the

Keywords: SNP; chemotherapy; leukopenia; neutropenia; polymorphism

Conflict of interest statement

CONFLICTS OF INTEREST Peter Fasching has received honoraria from Genomic Health, Teva, Novartis, Amgen, Pfizer, and Roche, and he has conducted research for Novartis and Amgen. Brigitte Rack has recei

References

  1. Support Care Cancer. 2011 Apr;19(4):483-90 - PubMed
  2. BMC Genomics. 2014 Feb 01;15:93 - PubMed
  3. J Natl Cancer Inst. 2014 May 15;106(5):null - PubMed
  4. BMC Cancer. 2011 Sep 23;11:404 - PubMed
  5. N Engl J Med. 2013 Mar 21;368(12):1131-9 - PubMed
  6. Stat Med. 1996 Feb 28;15(4):361-87 - PubMed
  7. Cancer. 2006 May 15;106(10):2258-66 - PubMed
  8. J Clin Oncol. 2000 Aug;18(16):3038-51 - PubMed
  9. J Clin Oncol. 2007 Jul 20;25(21):3158-67 - PubMed
  10. J Cancer Res Clin Oncol. 2013 Mar;139(3):419-27 - PubMed
  11. Ann Intern Med. 2007 Sep 18;147(6):400-11 - PubMed
  12. J Clin Oncol. 2010 Jul 10;28(20):3227-33 - PubMed
  13. J Clin Oncol. 2005 Jun 20;23(18):4198-214 - PubMed
  14. Support Care Cancer. 2006 Sep;14(9):901-9 - PubMed
  15. Strahlenther Onkol. 2007 Dec;183(12):661-6 - PubMed
  16. Cochrane Database Syst Rev. 2008 Oct 08;(4):CD003189 - PubMed
  17. Cancer. 2010 Dec 1;116(23):5555-63 - PubMed
  18. Ann Oncol. 2007 Feb;18(2):282-7 - PubMed
  19. Am J Epidemiol. 2004 May 1;159(9):882-90 - PubMed
  20. Eur J Cancer. 2006 Oct;42(15):2433-53 - PubMed
  21. Pharmacogenet Genomics. 2011 Sep;21(9):552-8 - PubMed
  22. Ann Oncol. 2009 Jan;20(1):34-40 - PubMed
  23. Cancer Res. 2008 Sep 1;68(17):7050-8 - PubMed
  24. Intensive Care Med. 2002 Dec;28(12):1775-80 - PubMed
  25. Geburtshilfe Frauenheilkd. 2013 Jan;73(1):63-69 - PubMed
  26. N Engl J Med. 2006 Dec 21;355(25):2631-9 - PubMed
  27. Br J Cancer. 2003 Nov 17;89(10):1837-42 - PubMed
  28. Biotechniques. 2002 Jun;Suppl:56-8, 60-1 - PubMed
  29. Strahlenther Onkol. 2008 Jul;184(7):347-53 - PubMed
  30. Ann Oncol. 2009 Mar;20(3):513-9 - PubMed
  31. Br J Haematol. 2009 Mar;144(5):677-85 - PubMed
  32. BMC Cancer. 2014 Mar 19;14:201 - PubMed
  33. Cancer. 2007 Oct 1;110(7):1611-20 - PubMed
  34. Oncologist. 2010;15(10 ):1063-72 - PubMed
  35. Eur J Cancer. 2011 Jan;47(1):8-32 - PubMed
  36. J Clin Oncol. 1992 Feb;10(2):316-22 - PubMed
  37. Cancer. 2009 Nov 15;115(22):5319-28 - PubMed
  38. Ann Oncol. 2013 Jun;24(6):1513-25 - PubMed
  39. Breast Cancer Res Treat. 2012 Jan;131(2):483-90 - PubMed
  40. N Engl J Med. 2006 Dec 21;355(25):2615-7 - PubMed
  41. Am J Clin Oncol. 2008 Aug;31(4):369-74 - PubMed
  42. J Infect. 2001 Feb;42(2):120-5 - PubMed
  43. Crit Rev Oncol Hematol. 2014 Jun;90(3):190-9 - PubMed
  44. Eur J Clin Microbiol Infect Dis. 1999 Aug;18(8):539-44 - PubMed
  45. Breast Cancer Res Treat. 2012 Apr;132(3):947-53 - PubMed
  46. Anticancer Res. 2010 May;30(5):1837-41 - PubMed

Publication Types

Grant support